←
Calico213 posts
Calico avatar

Calico

@calico

Calico is a research and development company tackling one of life's greatest mysteries, the biology that controls human aging.

◷ Joined June 2016▧ 123 Photos and videos
Calico avatar
Calico@calico·Nov 12

As Director of Financial Planning & Analysis, Ann Lei partners with business leaders and drug development teams to identify the financial insights and opportunities that help shape our path. We asked Ann what she enjoys most about working at Calico. calicolabs.com/life-at-calic…

Post attachment
Calico avatar
Calico@calico·Oct 27

Each round of lab results informs the next round of design to accelerate the development of potential peptide therapies. Read more in this Calico Story: calicolabs.com/story/camole-… (2/2)

0:39
Calico avatar
Calico@calico·Oct 27

Calico's new integrated machine learning platform, CAMOLE (Calico All-Atom Molecule Engine), pairs 3D generative modeling with iterative lab testing to explore new possibilities in therapeutic peptide design. (1/2)

Calico avatar
Calico@calico·Oct 15

As a Principal Data Scientist at Calico, Alejandro Granados builds computational methods that help move promising discoveries from our labs into Calico's translational programs. We asked Alejandro what he enjoys most about working at Calico. calicolabs.com/life-at-calic…

Post attachment
Calico avatar
Calico@calico·Oct 13

We look forward to connecting with pediatric neurologists and discussing research on Vanishing White Matter at the @ChildNeuroSoc Annual Meeting in Montréal, October 14-17. Stop by Booth 1319 to meet our team and pick up educational materials.

Post attachment
Calico avatar
Calico@calico·Oct 8

Fosigotifator is an investigational drug. It has not been approved by the FDA or any other regulatory authority. Its safety and effectiveness have not been established. (6/6)

Calico avatar
Calico@calico·Oct 8

Fosigotifator, an investigational compound designed to target eIF2B, is currently being studied in a Phase 1b/2 clinical trial in people with Vanishing White Matter, a rare brain condition. (4/6)

Calico avatar
Calico@calico·Oct 8

She later identified ISRIB, a molecule that activates the protein eIF2B to modulate cellular stress signals. Today at Calico, Carmela continues to lead research into this cellular stress pathway as her foundational work moves from the lab bench into clinical studies. (3/6)

Calico avatar
Calico@calico·Oct 8

During her early academic research, Carmela co-discovered a fundamental part of the unfolded protein response, demonstrating how protein-making machinery in the cell communicates with the nucleus during cellular stress. (2/6)

Calico avatar
Calico@calico·Oct 8

We're thrilled to see Carmela Sidrauski, Ph.D., Distinguished Principal Investigator at Calico, recognized as one of @endpts 20 Women Changing Biopharma! This honor highlights her scientific leadership in reshaping our understanding of how cells respond to stress. (1/6)

Post attachment
Calico avatar
Calico@calico·Sep 24

Thank you to our early-career scientists for bringing your energy, fresh perspectives, and spirit of curiosity. We're grateful you're here! Here are some moments from our recent Postdoc Summit. #NationalPostdocAppreciationWeek

0:14
Calico avatar
Calico@calico·Sep 22

September is #LeukodystrophyAwarenessMonth. Vanishing White Matter is a rare, progressive leukodystrophy that usually appears in early childhood. There's currently no approved treatment.

Calico avatar
Calico@calico·Sep 16

Our work now spans clinical- and early-stage programs across several aging and age-related disease areas, all of it building on the fundamental research that comes first. Thank you to our team, our collaborators, and everyone else who helped us get here.